Next™ BriefLipoprotein(a) Lowering Therapies and the First Outcome Trials
Buy Now
Meticulous Next™HealthcareNov 2026116 ppMRN-1805

Lipoprotein a lowering therapies Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1805Format: PDF + Summary DeckDelivery: InstantHorizon: 8-yr horizonSignal: High-impact
Buy Now · $1,250
Adoption maturity (indexed)
Mainstream inflection: ~2031
Horizon: 2026–2034 · Signal: High-impact
8 yrs
Forward horizon
~2031
Mainstream inflection
High impact
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines lipoprotein(a) lowering therapies, the RNA and oral medicines designed to cut the inherited blood particle that raises the risk of heart attack and stroke. It tests how the first cardiovascular outcome trial results reshape development, payer and prescribing decisions to 2034, and what that means for pharma firms, cardiologists and payers.

The first outcome result has arrived. On 4 September 2026 Novartis and Ionis announced that Lp(a)HORIZON, a trial of 8,323 patients with established cardiovascular disease and lipoprotein(a) of at least 70 mg/dL given pelacarsen 80 mg monthly, did not meet its primary endpoint. Full data presented on 7 November 2026 at the American Heart Association Scientific Sessions and published in the New England Journal of Medicine showed lipoprotein(a) falling 78.4%, with no reduction in cardiovascular events after a median follow-up of 4.7 years. The conclusion is that lowering the particle by about four fifths was not enough to cut events in established disease, and the simple version of the hypothesis is not supported.

The next readouts test a deeper reduction. Amgen states that the OCEAN(a)-Outcomes trial of olpasiran in secondary prevention is ongoing, that OCEAN(a)-PreEvent in primary prevention and OCEAN(a)-CCTA on coronary plaque are enrolling, and gives no timing for data. Trial records place primary completion of OCEAN(a)-Outcomes in March 2028 and of Eli Lilly ACCLAIM-Lp(a) for lepodisiran in March 2029. The conclusion is that the question of whether a deeper and longer reduction helps will be answered between 2028 and 2029, so developers and payers face a period of waiting.

Interpretation is divided. Analysts at William Blair flagged meaningful risk to outcomes trials of the class, and Citi said it would not declare the mechanism dead. The conclusion is that investment and prescribing in the class now follow the olpasiran and lepodisiran readouts, and not the first result.

The brief treats lipoprotein(a) lowering therapies as a high-impact signal with an eight year horizon to 2034. It identifies which developers, diagnostics firms and payers capture value under each trial outcome. It is a focused 116-page decision brief that presents an indicative trajectory rather than a segmented market model.

Brief Snapshot
ParameterDetails
Forward horizon2026–2034 (8 years)
Emerging forceLp(a) therapeutics
Technology readinessNo approved targeted therapy, with the first phase 3 outcome trial missed and two further outcome trials ongoing
Indicative market size & forecastThe lipoprotein(a) lowering therapies market, covering small interfering RNA, antisense and oral lipoprotein(a) inhibitors and lipoprotein apheresis for patients with elevated lipoprotein(a), and excluding LDL cholesterol, PCSK9 and other lipid-lowering therapies, is valued at USD 0.05–0.10 billion in 2026 and is projected to reach USD 1.28–2.56 billion by 2034, at a CAGR of 50%
Mainstream inflection~2031, when the olpasiran and lepodisiran outcome trials have read out and any positive result reaches approval and payer coverage
Signal strengthA missed first outcome trial and two pending outcome trials, against limited evidence on deeper reduction
Primary beneficiariesDevelopers with positive outcome data; diagnostics firms measuring lipoprotein(a); apheresis providers serving patients with high levels; payers with clear coverage criteria
Brief length / format116 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

Lipoprotein(a) is a particle that carries cholesterol and a protein called apolipoprotein(a), and its level is set largely by genes. High levels are linked to heart attack, stroke and aortic valve disease, and standard lipid medicines lower it little. The conclusion is that patients with high levels have had no targeted option, which is the gap these therapies address.

The leading medicines silence production of the protein in the liver. Pelacarsen is an antisense medicine given monthly, and olpasiran and lepodisiran are small interfering RNA medicines given at longer intervals. Phase 2 results for olpasiran and lepodisiran showed placebo-adjusted reductions close to the full level, against about 35% to 80% across doses for pelacarsen. The conclusion is that the later trials test a deeper reduction than the first.

Pelacarsen has now reduced lipoprotein(a) by 78.4% without reducing events. Genetic studies estimate that a large absolute fall is needed to match the benefit of lowering LDL cholesterol, and lifelong exposure may differ from late treatment in established disease. The conclusion is that depth of reduction, timing in life and patient selection are open questions for the next trials.

The limits are trial risk, long event-driven timelines, the cost of outcome trials and the lack of a proven benefit. The brief tests each limit against the evidence to 2034.

Market Outlook

The lipoprotein(a) lowering therapies market, covering small interfering RNA, antisense and oral lipoprotein(a) inhibitors and lipoprotein apheresis for patients with elevated lipoprotein(a), and excluding LDL cholesterol, PCSK9 and other lipid-lowering therapies, is valued at USD 0.05–0.10 billion in 2026 and is projected to reach USD 1.28–2.56 billion by 2034, at a CAGR of 50%.

The 2026 base rests on lipoprotein apheresis for patients with elevated lipoprotein(a) and early use of targeted therapies in trials and access programmes, at current prices, which excludes LDL cholesterol, PCSK9 and other lipid-lowering therapies. Growth follows the outcome trial results, approval timing, the number of patients with elevated lipoprotein(a) who are identified and the price per patient year.

The forecast is sensitive to the olpasiran and lepodisiran results, regulatory decisions, payer coverage and the scale of lipoprotein(a) testing.

Scenarios

Scenarios.

The base case assumes at least one of the next outcome trials shows benefit, with approval around 2030 and coverage in 2031, bringing the inflection to 2031 and a 2034 value near the middle of the range. An accelerated case assumes an early positive olpasiran result and fast approval, moving the inflection to 2029 and lifting the 2034 value to the top of the range. A delayed case assumes the later trials also fail or read out late, moving the inflection beyond 2034 and holding value at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Large population with elevated lipoprotein(a).
  • No targeted therapy for patients with high levels.
  • Deeper reducing medicines in outcome trials.
  • Growing lipoprotein(a) testing.

Enablers

  • Large outcome trials in secondary and primary prevention.
  • Long-acting RNA medicines.
  • Guideline interest in measuring lipoprotein(a).
  • Royalty and partnership financing of development.

Restraints and barriers

  • First outcome trial missed its primary endpoint.
  • Long and costly event-driven trials.
  • Payer need for outcome evidence.
  • Uncertainty over the level and timing of reduction needed.

The Forces at Play

The direction of lipoprotein(a) lowering therapies is set by outcome trial results, regulatory decisions, payer coverage and the scale of testing.

The brief assesses standards and policy, company and investor funding, technology readiness, product readiness and customer readiness, and rates each force for direction, speed and confidence.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2028
Reassessment

Developers and payers reassess the class after the first outcome result while testing expands.

Mid term2028–2031
Second readouts

Olpasiran and lepodisiran outcome results decide whether the class reaches approval.

Long term2031–2034
Evidence-led adoption

Positive results lead to launches and coverage, and negative results lead to exit or narrow use.

Latest Strategic Developments

DateDevelopmentTypeSignificance
Feb 2019Novartis takes the licence option for pelacarsen from IonisLicensingFunds the first outcome trial
Aug 2023Novartis and Ionis sign a next-generation Lp(a) collaboration with a USD 60 million upfront paymentCollaborationExtends the class with a second programme
Sep 2025The design of Lp(a)HORIZON is published in the American Heart JournalPublicationSets the outcome trial design on record
Sep 2026Novartis and Ionis report that Lp(a)HORIZON did not meet its primary endpointTrial resultFirst outcome result for the class
Nov 2026Amgen reports OCEAN(a)-Outcomes ongoing and OCEAN(a)-PreEvent and OCEAN(a)-CCTA enrollingUpdateConfirms next outcome trials continue
Nov 2026Full Lp(a)HORIZON data are presented at the American Heart Association Scientific Sessions and published in the New England Journal of MedicineTrial resultGives the first full outcome dataset

Key Players & Competitive Landscape

The key participants in lipoprotein(a) lowering therapies include Novartis AG, Ionis Pharmaceuticals, Inc., Amgen Inc., Eli Lilly and Company, Silence Therapeutics plc, Arrowhead Pharmaceuticals, Inc., Royalty Pharma plc, Merck & Co., Inc., AstraZeneca PLC, Novo Nordisk A/S, Pfizer Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Esperion Therapeutics, Inc., NewAmsterdam Pharma Company N.V., Kaneka Corporation, Fresenius Medical Care AG, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, among others.

The brief profiles representative participants in each archetype and assesses which are positioned to lead under each outcome trial scenario.

Competitive intensity is low among Lp(a) developers today and rises sharply if outcome trials succeed, with entry barriers set by outcome trial size, manufacturing of RNA medicines and payer evidence.

ArchetypeRepresentative playersPosition in 2026Outlook to 2034
Lp(a) developers with outcome trialsNovartis AG, Ionis Pharmaceuticals, Inc., Amgen Inc., Eli Lilly and Company, Silence Therapeutics plc, Arrowhead Pharmaceuticals, Inc.Antisense, small interfering RNA and oral Lp(a) inhibitorsComplete outcome trials and prepare launch
Royalty and financing firmsRoyalty Pharma plcDevelopment financingFund trials against royalties
Lipid therapy incumbentsMerck & Co., Inc., AstraZeneca PLC, Novo Nordisk A/S, Pfizer Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Esperion Therapeutics, Inc., NewAmsterdam Pharma Company N.V.LDL cholesterol and cardiovascular medicinesCompete for the cardiovascular prevention budget
Apheresis providersKaneka Corporation, Fresenius Medical Care AGLipoprotein apheresisServe patients with very high levels
Diagnostics firmsQuest Diagnostics Incorporated, Laboratory Corporation of America HoldingsLipoprotein(a) testingIdentify patients with elevated levels

Where value migrates.

In 2026 value sits with developers holding outcome trials and with testing and apheresis providers serving patients today. By 2031 it moves toward the developers with positive results and toward payers that set coverage criteria. By 2034 it settles with the one or two medicines with proven benefit and the diagnostics that find eligible patients, or it leaves the class if outcome trials fail. Margins follow the evidence.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Developers with positive outcome data

Proven benefit unlocks approval and coverage.

Diagnostics firms with scaled Lp(a) testing

Testing finds eligible patients.

Payers with clear coverage criteria

Clear criteria limit spend to proven benefit.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
Novartis and IonisLp(a)HORIZON primary endpoint not metSeptember 2026First outcome result for the class
American Heart Association Scientific SessionsFull Lp(a)HORIZON data presented with simultaneous publicationNovember 2026Gives the first full outcome dataset
AmgenOCEAN(a)-Outcomes ongoing, with primary completion in March 2028March 2028Next outcome result
AmgenOCEAN(a)-PreEvent enrolling in primary prevention2026Tests earlier treatment
Eli LillyACCLAIM-Lp(a) with primary completion in March 2029March 2029Third outcome result

Investment Signals

The large population with high lipoprotein(a), the lack of targeted therapy, deeper reducing medicines and growing testing support growth, while the missed first outcome trial, long trial timelines, payer demand for outcome evidence and uncertainty over the reduction needed hold back the pace.

The olpasiran readout, the lepodisiran readout, subgroup analysis of Lp(a)HORIZON or a guideline change would shift the pace. The brief therefore tracks four indicators: outcome trial results, regulatory filings, payer coverage and testing volumes.

Reassessment, then second readouts, then evidence-led adoption is the expected order of change.

Questions This Brief Answers

01What is lipoprotein(a), and why are lowering therapies being tested?
02What is the market size in 2026, and what is the forecast to 2034?
03What did the first outcome trial show, and which trials follow?
04What factors are driving growth, and what barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will outcome trial results and payer decisions shape the market between 2026 and 2034?
08What should pharma firms, cardiologists, payers and investors do now?

Strategic Implications

  • Pharma firms: weigh trial spend against the olpasiran and lepodisiran readouts and plan launch only after positive outcome data.
  • Cardiologists: measure lipoprotein(a) once and treat high values through apoB and LDL cholesterol lowering until outcome evidence arrives.
  • Payers: set coverage criteria that wait for outcome data and define the eligible patient group early.
  • Diagnostics and apheresis providers: scale testing and prepare for a change in eligible patient numbers under each trial outcome.
  • Investors: treat the class as binary on the next two readouts, and size positions to the timing of March 2028 and March 2029.
Analyst Perspective

"A particle can be lowered by four fifths and still not move the event count."

Lead Foresight Analyst
Healthcare & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$1,250
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,750
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,050
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries